The ingredients discovered in the first stop were not yet in the form of the finished drug.

FORBES: Supreme Court Says K-9 Dog's Sniff Was Up To Snuff

Novartis is also conducting full-scale head-to-head studies with Vioxx and Celebrex to try and prove that Prexige is the safest of the three, but these are not expected to be finished until after the drug goes before the Food and Drug Administration.

FORBES: Magazine Article

The two biotech firms have finished their safety review of Tysabri, the multiple sclerosis drug that the companies pulled from the market on Feb. 28 after it was linked to a rare brain disorder.

FORBES: Tysabri Still Down, But Not Out

Genentech has finished filing its application with the U.S. Food and Drug Administration to sell Avastin as a treatment for colorectal cancer.

FORBES: Magazine Article